The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs.
Grob
C S
CS
Department of Psychiatry, University of California, Irvine Medical Center, Orange 92668.
Bravo
G L
GL
Walsh
R N
RN
Liester
M B
MB
D015104:3,4-Methylenedioxyamphetamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D003131:Combined Modality Therapy; D015198:Designer Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000628:therapy; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009420:Nervous System / Q000187:drug effects*; D009422:Nervous System Diseases / Q000139:chemically induced; D011613:Psychotherapy; D012107:Research Design / Q000592:standards; D012701:Serotonin / Q000502:physiology; D019966:Substance-Related Disorders / Q000209:etiology / Q000523:psychology; D009435:Synaptic Transmission / Q000187:drug effects
D015198:Designer Drugs; D012701:Serotonin; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine